Advertisement
Canada markets closed

  • S&P/TSX

    21,642.87
    -97.33 (-0.45%)
     

  • S&P 500

    5,051.41
    -10.41 (-0.21%)
     

  • DOW

    37,798.97
    +63.86 (+0.17%)
     

  • CAD/USD

    0.7236
    +0.0003 (+0.04%)
     

  • CRUDE OIL

    85.28
    -0.08 (-0.09%)
     

  • Bitcoin CAD

    88,227.93
    +744.51 (+0.85%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • GOLD FUTURES

    2,399.80
    -8.00 (-0.33%)
     

  • RUSSELL 2000

    1,967.48
    -8.23 (-0.42%)
     

  • 10-Yr Bond

    4.6590
    +0.0310 (+0.67%)
     

  • NASDAQ futures

    17,910.50
    +29.25 (+0.16%)
     

  • VOLATILITY

    18.40
    -0.83 (-4.32%)
     

  • FTSE

    7,820.36
    -145.17 (-1.82%)
     

  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     

  • CAD/EUR

    0.6809
    +0.0001 (+0.01%)
     
BREAKING:

$535B CANADA BUDGET PROJECTS $39.8B DEFICIT, AIMS TO RESTORE ECONOMIC FAIRNESS

It seeks to ease the housing and affordability crisis by making older, wealthier Canadians pay more

OHR Pharmaceutical (OHRP) is now in Oversold Territory

Zacks Equity Research

OHR Pharmaceutical Inc ’s (OHRP) share price has entered into oversold territory with an RSI value of 27.7. The Zacks Consensus Estimate for OHR Pharmaceutical for the full year period has improved 27 cents over the past two months to -53 cents per share. Currently, OHR Pharmaceutical has a Zacks Rank #2 (Buy), suggesting that now might be a good time to get in on (OHRP) after its recent drop.




OHR PHARMACEUTICAL INC (OHRP): Free Stock Analysis Report


Zacks Investment Research